Trials / Completed
CompletedNCT04580303
CCH Treatment of Cellulite in the Presence of Dermal Laxity With Comparison Between Two (2) Different Injection Techniques
A Phase 2 Multicenter, Open-label, Randomized, Parallel-group, Multiple-dose Study to Assess the Effectiveness, Safety and Satisfaction With Collagenase Clostridium Histolyticum Grid Technique Injections of Buttock or Thigh Cellulite With Laxity in Adult Females
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Endo Pharmaceuticals · Industry
- Sex
- Female
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This study is designed to investigate the safety and efficacy of collagenase clostridium histolyticum (CCH) for the treatment of mild to moderate edematous fibrosclerotic panniculopathy (cellulite) in participants with moderate to severe dermal laxity in the buttocks or thighs with comparison between two (2) different CCH injection techniques.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | collagenase clostridium histolyticum | Delivered via uniform grid injection techniques. |
Timeline
- Start date
- 2020-10-01
- Primary completion
- 2021-08-30
- Completion
- 2021-09-24
- First posted
- 2020-10-08
- Last updated
- 2022-09-28
- Results posted
- 2022-09-28
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04580303. Inclusion in this directory is not an endorsement.